ArticleCureus2026
Estimation of Serum Calponin-2 in Patients With Breast Carcinoma and Its Clinicopathological Correlation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast carcinoma represents a major health burden among women in India. Identifying serum biomarkers like calponin-2 could aid in diagnosis, tumor burden assessment, and prognosis.
objectiveTo estimate serum calponin-2 levels in patients with breast carcinoma and evaluate correlations with clinicopathological parameters. PATIENTS AND
methodsThis prospective observational study was conducted at Jawaharlal Nehru Medical College, Aligarh Muslim University, from May 2023 to May 2025. Fifty histologically confirmed breast cancer patients were enrolled. Serum calponin-2 levels were measured pre- and postoperatively using ELISA. Clinicopathological features, including tumor size, grade, TNM stage, receptor status, and molecular subtype, were analyzed. Statistical analyses included paired
resultsThe mean patient age was 46.1 years, with the highest incidence in the 40-50 age group. Luminal B and HER2-enriched subtypes predominated. A significant postoperative decline in calponin-2 levels (mean reduction: 10.5%) was noted. Preoperative calponin-2 showed significant correlation with tumor size (ρ = 0.306, p = 0.030), T stage (ρ = 0.348, p = 0.015), and node positivity (ρ = 0.315, p = 0.021).
conclusionSerum calponin-2 correlates with tumor aggressiveness and shows promise as a tumor burden biomarker in breast carcinoma. It holds potential for integration into routine diagnostic panels, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.